Challenges in developing Geroscience trials.

Nir Barzilai, Rafael de Cabo, Yves Rolland, Felipe Sierra, Luigi Ferrucci, Joan Mannick, Anthony Oliva, William Evans, Davide Angioni, Philipe De Souto Barreto, Jeremy Raffin, Bruno Vellas, James L Kirkland

Journal: Nature communications 2023;14(1):5038

PMID: 37598227

Free Full Text on Nature Publishing Group View on PubMed

Abstract

Geroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses ("Gerodiagnostics"). This article reports the main results of a Task Force of experts in Geroscience.

Address: Gérontopôle de Toulouse, IHU HealthAge, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France. [email protected].; CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France. [email protected].; Hevolution Foundation, Riyadh, Saudi Arabia.; National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.; Institute for Aging Research, Albert Einstein College of Medicine, Bronx, NY, USA.; Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.; Life Biosciences, Boston, MA, USA.; Longeveron Inc., Miami, FL, USA.; Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, USA.; Gérontopôle de Toulouse, IHU HealthAge, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.; CERPOP UMR 1295, University of Toulouse III, Inserm, UPS, Toulouse, France.; Noaber Foundation Professor of Aging Research, Mayo Clinic, Principal Investigator, NIH R33 Translational Geroscience Network, President, American Federation for Aging Research, Rochester, NY, USA.

DOI: 10.1038/s41467-023-39786-7

Link outs

Free resources

Full Text Sources:

MeSH Terms: Humans, Geroscience, Advisory Committees, Aging, Research Personnel